Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

23.89USD
22 Jul 2016
Change (% chg)

-- (--)
Prev Close
$23.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,102,747
52-wk High
$41.94
52-wk Low
$8.00

SRPT.OQ

Chart for SRPT.OQ

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $1,144.96
Shares Outstanding(Mil.): 47.93
Dividend: --
Yield (%): --

Financials

  SRPT.OQ Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -5.01 -- --
ROI: -118.93 -5.86 14.35
ROE: -128.48 -4.70 15.56

BRIEF-Sarepta Therapeutics Q2 non-GAAP loss per share $1.19 excluding items

* No revenue was recognized for three months ended June 30, 2016 and 2015

Jul 19 2016

BRIEF-Sarepta Therapeutics announces proposed offering

* Sarepta Therapeutics Inc says intends to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering

Jun 08 2016

UPDATE 2-Sarepta says FDA asks for more data for its muscle-wasting treatment

June 6 Sarepta Therapeutics Inc said the U.S. Food and Drug Administration has requested for additional data from an ongoing study for its muscle-wasting treatment as the agency decides whether to approve the drug or not.

Jun 06 2016

Sarepta says FDA asks for more data for its muscle-wasting treatment

Sarepta Therapeutics Inc said the U.S. Food and Drug Administration has requested for additional data for its muscle-wasting treatment as the agency decides whether to approve the drug or not.

Jun 06 2016

Sarepta says FDA asks for more data for its muscle-wasting treatment

June 6 Sarepta Therapeutics Inc said the U.S. Food and Drug Administration has requested for additional data for its muscle-wasting treatment as the agency decides whether to approve the drug or not.

Jun 06 2016

BRIEF-Sarepta Therapeutics announces FDA request for dystrophin data

* Sarepta Therapeutics announces FDA request for dystrophin data prior to making a decision on eteplirsen NDA

Jun 06 2016

Experimental drugs for compassionate use to sell only at cost: FDA

The U.S. Food and Drug Administration said companies could only charge patients for the cost of manufacturing experimental treatments used under compassionate grounds, and it cannot force government or private health insurers to pay for these drugs.

Jun 02 2016

UPDATE 1-Experimental drugs for compassionate use to sell only at cost: FDA

June 2 The U.S. Food and Drug Administration said companies could only charge patients for the cost of manufacturing experimental treatments used under compassionate grounds, and it cannot force government or private health insurers to pay for these drugs.

Jun 02 2016

Drugmakers can't charge beyond making costs for compassionate use: FDA

June 2 The U.S. Food and Drug Administration said companies could only charge patients for the cost of manufacturing experimental treatments used under compassionate grounds, and it cannot force government or private health insurers to pay for these drugs.

Jun 02 2016

S&P 500 ascends 2 percent in two days

Wall Street rose robustly for a second straight session on Wednesday, helped by higher oil prices and investors becoming more comfortable with the prospect of an interest rate hike as early as next month. | Video

May 25 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.